Entrada Therapeutics, Inc.

What they do

Entrada is advancing a pipeline of exon-skipping therapies for DMD, using its endosomal escape vehicle (EEV) platform to deliver oligonucleotides to intracellular targets. Its lead programs are ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51, along with a partnered DM1 program (VX-670) with Vertex. The company is conducting global clinical trials and has not yet generated product revenue, funding operations through partnerships and capital raises.

Revenue drivers

• Collaboration revenue — Revenue from the Vertex partnership (VX-670) and other collaborations; annual revenue fell from $210.8M in 2024 to $25.4M in 2025 as milestone-driven revenue declined.
• Contract and grant revenue — Minimal revenue from research contracts or grants; quarterly revenue in 2025-2026 was under $2M per quarter.
• Milestone payments — Future payments from partners tied to clinical and regulatory milestones; not yet a stable revenue stream.

Recent performance

For Q2 2026, revenue was $898,000, down from $1.6M in Q3 2025 and $1.3M in Q4 2025. Net income for 2025 was a loss of $143.8M versus income of $65.6M in 2024, primarily due to reduced partner revenue and higher R&D costs. Operating cash flow was negative $128.5M in 2025. As of June 30, 2026, cash and marketable securities were $223.0M, with total assets of $298.9M and shareholder equity of $233.4M.

Strategy

The company is prioritizing clinical execution across its DMD franchise, aiming to generate data that supports accelerated approval in the U.S. It plans to expand the ELEVATE-44-201 study with an expansion cohort and is evaluating higher doses in other trials. Management expects readouts from one program to inform the others due to the shared EEV platform. It is also engaging with regulators on trial design and timing for adult patients (ELEVATE-44-102) and advancing regulatory submissions for ENTR-601-50 and ENTR-601-51.

Risks

• Clinical trial risk — Failure to demonstrate safety or efficacy in ongoing Phase 1/2 trials could halt development of the entire DMD franchise.
• Regulatory risk — Delays or negative feedback from FDA, MHRA, or EU authorities could alter trial designs and timelines, especially for ELEVATE-44-102 and ENTR-601-50.
• Cash runway risk — With $223.0M in cash as of June 30, 2026, management expects funding into Q3 2027, but negative operating cash flow may require additional capital before key data readouts.
• Partnership dependency — Revenue and program progress depend on the Vertex collaboration; if Vertex terminates or fails to share positive VX-670 data, future milestones and credibility could be impacted.

Outlook

Management expects a catalyst-rich period in 2026-2027, with ELEVATE-45-201 Cohort 1 data in October 2026, ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, and ELEVATE-44-201 Cohort 2 data in Q1 2027. They also anticipate Vertex reporting VX-670 Phase 1/2 data in DM1 in H2 2026. The company plans to submit EU regulatory applications for ENTR-601-50 by year-end 2026 and complete INDs for ENTR-601-51.